Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $98.93.
Several research firms have recently issued reports on ARWR. The Goldman Sachs Group began coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They set a "neutral" rating and a $74.00 price objective on the stock. Chardan Capital reiterated a "buy" rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reissued a "buy" rating and set a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. UBS Group initiated coverage on Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. They set a "buy" rating and a $109.00 price target on the stock. Finally, Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd.
Check Out Our Latest Analysis on Arrowhead Pharmaceuticals
Institutional Trading of Arrowhead Pharmaceuticals
Institutional investors have recently modified their holdings of the company. Lighthouse Investment Partners LLC increased its position in shares of Arrowhead Pharmaceuticals by 85.4% during the third quarter. Lighthouse Investment Partners LLC now owns 13,905 shares of the biotechnology company's stock valued at $910,000 after purchasing an additional 6,405 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $256,000. State of Tennessee Department of Treasury lifted its position in Arrowhead Pharmaceuticals by 22.3% in the third quarter. State of Tennessee Department of Treasury now owns 54,757 shares of the biotechnology company's stock worth $3,584,000 after purchasing an additional 10,001 shares during the period. Cetera Investment Advisers lifted its position in Arrowhead Pharmaceuticals by 17.0% in the third quarter. Cetera Investment Advisers now owns 34,215 shares of the biotechnology company's stock worth $2,239,000 after purchasing an additional 4,974 shares during the period. Finally, EP Wealth Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 0.9% in the third quarter. EP Wealth Advisors LLC now owns 38,471 shares of the biotechnology company's stock worth $2,518,000 after purchasing an additional 336 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.
Arrowhead Pharmaceuticals Price Performance
NASDAQ:ARWR opened at $44.21 on Tuesday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a one year low of $37.06 and a one year high of $95.49. The company has a fifty day moving average price of $62.48 and a 200 day moving average price of $70.90. The stock has a market cap of $6.23 billion, a P/E ratio of -8.65 and a beta of 1.34.
Arrowhead Pharmaceuticals Company Profile
(
Get Free Report)
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company's research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.